A New Frontier in Immuno-Oncology

actym therapeutics word
actym therapeutics logo

Targeting intractable immune pathways in the tumor microenvironment

Management Team

President, CEO, and Cofounder
Vice President of Research and Cofounder
Chief Medical Advisor
Head of Operations

Scientific Advisory Board

Greg Barton, Ph.D.
Samuel Miller, M.D.
Denise Monack, Ph.D.
Paul Rennert, Ph.D. 
Mario Sznol, M.D.

Clinical Advisory Board

Joel Randolph Hecht, M.D.
Jason Luke, M.D.
Mario Sznol, M.D.
Jean Pierre Bizzari, M.D.


BERKELEY, Calif., April 27, 2020   

Financing will fund Actym’s cancer immunotherapy pipeline into clinical development

BERKELEY, Calif., Nov 7, 2019  PRNewswire

The presentation will highlight Actym’s novel tumor-specific therapies that deliver multiplexed immunomodulatory payloads after systemic administration.

BERKELEY, Calif., April 10, 2019

Actym Therapeutics announced that Dr. Christopher Thanos, President, CEO, and Cofounder, has been invited to speak at the 15th annual PEGS Conference in Boston, MA.

Apr 02, 2019 PRNewswire

Two presentations will highlight Actym's novel IV administered, tumor-infiltrating therapies that express immuno-modulatory factors

Nov 8, 2018 PRNewswire

Presentation will focus on a novel tumor-targeting, systemically-delivered STING pathway agonist that demonstrates robust anti-tumor efficacy in multiple murine cancer models.


Contact Us

Actym Therapeutics

626 Bancroft Way

Suite A

Berkeley, CA 94710